Pasar al contenido principal

Cell organelles as signaling hubs in disease: novel roles in mechanoadaption and innate immunity

RYC2020-029690-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective

  • López-Méndez, Tania Belén
  • Sánchez-Álvarez, Miguel
  • Trionfetti, Flavia
  • Pedraz, José Luís
  • Tripodi, Marco
  • Cordani, Marco
  • Strippoli, Raffaele
  • González-Valdivieso, Juan
In recent years, progress in nanotechnology provided new tools to treat cancer more effectively. Advances in biomaterials tailored for drug delivery have the potential to overcome the limited selectivity and side effects frequently associated with traditional therapeutic agents. While autophagy is pivotal in determining cell fate and adaptation to different challenges, and despite the fact that it is frequently dysregulated in cancer, antitumor therapeutic strategies leveraging on or targeting this process are scarce. This is due to many reasons, including the very contextual effects of autophagy in cancer, low bioavailability and non-targeted delivery of existing autophagy modulatory compounds. Conjugating the versatile characteristics of nanoparticles with autophagy modulators may render these drugs safer and more effective for cancer treatment. Here, we review current standing questions on the biology of autophagy in tumor progression, and precursory studies and the state-of-the-art in harnessing nanomaterials science to enhance the specificity and therapeutic potential of autophagy modulators., Work in the laboratories of the authors is funded by grants from the Italian Ministries for Health (Ricerca Corrente) to M.T., from Education, University and Research (MIUR; 000003_17_MAP_STRIP and FISR 2020-Covid FISR2020IP_03366) to R.S; and from the Spanish Ministerio de Ciencia e Innovación (PID2021-128106NA-I00). M.C. is currently a recipient of a Ramón y Cajal tenure track contract from the Spanish Ministry of Science and Innovation (RYC2021-031003-I) and was funded by “Maria Zambrano” contract from Spanish Ministry of Universities and Complutense University of Madrid. M.S-A is recipient of a Ramón y Cajal tenure track contract from the Spanish Ministry of Science and Innovation (RYC2020-029690-I)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Survey for Human Tissue-Level Determinants of CAV1 Regulation and Function

  • Jiménez-Jiménez, Victor
  • Sánchez Cabo, Fátima
  • Schwartz, Martin A.
  • Sánchez-Álvarez, Miguel
  • Pozo, Miguel Angel
CAV1 is a protein-coding gene linked to several disorders, including cancer, lipodystrophy, and cardiovascular diseases. While its ability to respond to various mechanical and metabolic stimuli has been documented, a comprehensive understanding of its physiological regulation in humans is lacking. We leveraged the comprehensiveness of human post-mortem tissue data from the Genotype-Tissue Expression (GTEx) consortium, systematically exploring the sources of variability in CAV1 transcriptional levels using extensive bulk and single-nuclei RNA-seq datasets. This human-centric approach, avoiding inter-species comparisons, constitutes a unique resource to explore CAV1 regulation within the complexity of human tissues. Notably, cell type proportion was identified as a major determinant of CAV1 transcription levels across tissues. Donor physiological conditions, including disease states and end-of-life circumstances, also exhibited a tissue-specific influence. Among primary upstream regulators associated with CAV1, chromatin modifiers stood out, especially SMARCA2, which showed a positive correlation across tissues, and PRC2 complexes, which exhibited tissue-specific correlation. Upstream regulatory networks determining CAV1 levels are also enriched for annotations such as mechanobiology (e.g., TEAD4), immunity (e.g., RELA and STAT3), and metabolism (e.g., MYC and NRF1). A remarkable observation was a strong correlation between CAV1 and the relative infiltration of immune cells across tissues, supporting a potential role for CAV1 as a marker and driver of tissue immune infiltration., M.Á.d.P. is a recipient of grants from the Spanish Ministry of Science and Innovation (MCIN) (refs. SAF2017–83130-R cofunded by “ERDF A way of making Europe”, PID2020-118658RB-I00, PDC2021–121572-100 cofunded by “European Union NextGeneration EU/PRTR”), Asociación Española Contra el Cáncer foundation (AECC; PROYE20089DELP); La Marató TV3 foundation (201936–30-31), Fundación Obra social La Caixa (AtheroConvergence, HR20–00075; of which he is the coordinator) and Comunidad Autónoma de Madrid/FEDER (Tec4Bio consortium, ref. S2018/NMT¬4443). M.S.-Á. is a recipient of a Ramón y Cajal research contract from MCIN (RYC2020–029690-I) and research grants PID2021-128106NA-I00 and CNS2023-144831, all from Spanish MCIN. M.Á.d.P. received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement 641639 in the context of the BIOPOL ITN consortia, of which V.J.-J. was an ESR. V.J.-J. was also supported by the La Caixa and Deutscher Akademischer Austauschdienst scholarship. M.A.S. is Robert W. Berliner Professor of Medicine and co-recipient of the AtheroConvergence grant from Fundación Obra social La Caixa (HR20–00075). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN), and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033). The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001041-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PERK-dependent reciprocal crosstalk between ER and non-centrosomal microtubules coordinates ER architecture and cell shape

  • Sánchez-Álvarez, Miguel
  • Nicolás Lolo, Fidel
  • Sailem, Heba
  • Fulgoni, Giulio
  • Pascual, Patricia
  • Agüera, Lucía
  • Catalá-Montoro, Mauro
  • Arias-García, Mar
  • López, Juan Antonio
  • Vázquez, Jesús
  • Pozo, Miguel Angel
  • Bakal, Chris
The architecture of the endoplasmic reticulum (ER) is a key determinant of its function. Its dynamics are linked to those of the cytoskeleton, but our understanding of how this coordination occurs and what its functional relevance is, limited. Here, we report that the unfolded protein response (UPRER) transducer EIF2AK3/PERK (eukaryotic translation initiation factor 2-alpha kinase 3/protein kinase R-like endoplasmic reticulum kinase) is essential for acute-stress-induced peripheral redistribution and remodeling of the ER through eukaryotic initiation factor 2 alpha (eIF2α) phosphorylation and translation initiation shutdown. PERK-mediated eIF2α phosphorylation can be bypassed by blocking polysome assembly, depleting microtubule (MT)-anchoring ER proteins such as p180/RRBP1 (ribosome-binding protein 1), or disrupting the MT cytoskeleton. Specific disruption of non-centrosomal MTs, but not centrosome depletion, rescues ER redistribution in PERK-deficient cells. Conversely, PERK deficiency stabilizes non-centrosomal MTs against proteasomal degradation, promoting polarized protrusiveness in epithelial cells and neuroblasts. Thus, PERK coordinates ER architecture and homeostasis with cell morphogenesis by coupling ER remodeling and non-centrosomal MT stability and dynamics., Light microscopy and dynamic imaging/ICTS-ReDib at CNIC is supported by MCIN/AEI/10.13039/501100011033 and FEDER “Una manera de hacer Europa” (#ICTS-2018-04-CNIC-16; Madrid, Spain). Amine Sadok and Faraz Mardakheh (former researchers at ICR, London, UK) provided expert advice and assistance with collagen migration experiments. C.B. and H.S. have been beneficiaries of the Wellcome Trust Career Development Fellowship program. Funding support at the C.B. lab was received from the Cancer Research UK (CRUK) Programme Foundation Award (C37275/A20146) and the Stand Up to Cancer campaign. M.S.-A. was a fellow of the COFUND-IPP program (CNIC); is a recipient of grants from the Spanish Ministerio de Ciencia e Innovación (MICINN; RYC2020-029690-I and PID2021-128106NA-I00) and the Scientific Foundation, Spanish Association Against Cancer (LAB AECC 2024 grant LABAE246690SANC); and is supported by consolidation grant CNS2023-144831, sponsored by Ministerio de Ciencia, Innovación y Universidades (MICIU)/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR. The M.A.d.P. lab is sponsored by Spanish Ministerio de Ciencia e Innovación (MCNU; PID2020-118658RB-I00, SAF2017-83130-R, and BFU2016-81912-REDC); the Comunidad Autónoma de Madrid/FEDER, Spain (ref. S2018/NMT4443; Actividades de I+D entre Grupos de Investigación en Tecnologías); Obra Social La Caixa (AtheroConvergence-HR20-00075); and the Fundació la Marató de TV3 (385/C/2019). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovación y Universidades (MICIU), and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033). The M.S-A. laboratory is a member of the RER-CSIC rare disease research network., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001041-S)., Peer reviewed